Congress Park Capital’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $230K | Buy |
9,551
+2,125
| +29% | +$55.6K | 0.06% | 119 |
|
|
2026
Q1 | $209K | Sell |
7,426
-1,500
| -17% | -$39.9K | 0.06% | 127 |
|
|
2025
Q4 | $222K | Hold |
8,926
| – | – | 0.07% | 120 |
|
|
2025
Q3 | $227K | Buy |
8,926
+375
| +4% | +$9.26K | 0.07% | 113 |
|
|
2025
Q2 | $207K | Buy |
8,551
+536
| +7% | +$12.5K | 0.07% | 113 |
|
|
2025
Q1 | $203K | Sell |
8,015
-500
| -6% | -$13.1K | 0.08% | 103 |
|
|
2024
Q4 | $226K | Sell |
8,515
-750
| -8% | -$20.3K | 0.08% | 105 |
|
|
2024
Q3 | $268K | Sell |
9,265
-2,375
| -20% | -$69.3K | 0.1% | 103 |
|
|
2024
Q2 | $326K | Sell |
11,640
-10,000
| -46% | -$275K | 0.13% | 96 |
|
|
2024
Q1 | $601K | Buy |
21,640
+2,000
| +10% | +$55.5K | 0.27% | 72 |
|
|
2023
Q4 | $565K | Sell |
19,640
-6,905
| -26% | -$209K | 0.28% | 72 |
|
|
2023
Q3 | $880K | Buy |
26,545
+1,399
| +6% | +$49.5K | 0.46% | 49 |
|
|
2023
Q2 | $922K | Buy |
25,146
+1,258
| +5% | +$49K | 0.46% | 51 |
|
|
2023
Q1 | $975K | Buy |
23,888
+3,250
| +16% | +$140K | 0.51% | 46 |
|
|
2022
Q4 | $1.06M | Buy |
20,638
+450
| +2% | +$21.6K | 0.62% | 45 |
|
|
2022
Q3 | $883K | Buy |
20,188
+2,450
| +14% | +$119K | 0.51% | 47 |
|
|
2022
Q2 | $930K | Buy |
17,738
+1,137
| +7% | +$57.9K | 0.56% | 44 |
|
|
2022
Q1 | $859K | Sell |
16,601
-2,400
| -13% | -$125K | 0.43% | 60 |
|
|
2021
Q4 | $1.12M | Buy |
19,001
+250
| +1% | +$12.4K | 0.55% | 47 |
|
|
2021
Q3 | $806K | Buy |
18,751
+250
| +1% | +$11.1K | 0.41% | 59 |
|
|
2021
Q2 | $724K | Buy |
18,501
+500
| +3% | +$19.4K | 0.36% | 62 |
|
|
2021
Q1 | $652K | Buy |
18,001
+1,725
| +11% | +$61.2K | 0.36% | 67 |
|
|
2020
Q4 | $599K | Buy |
16,276
+702
| +5% | +$25.8K | 0.35% | 62 |
|
|
2020
Q3 | $542K | Buy |
15,574
+2,446
| +19% | +$85.8K | 0.34% | 56 |
|
|
2020
Q2 | $407K | Buy |
13,128
+1,608
| +14% | +$54.6K | 0.31% | 62 |
|
|
2020
Q1 | $357K | Buy |
11,520
+2,608
| +29% | +$88.9K | 0.32% | 58 |
|
|
2019
Q4 | $331K | Sell |
8,912
-426
| -5% | -$15.2K | 0.24% | 74 |
|
|
2019
Q3 | $318K | Buy |
9,338
+4
| +0% | +$145 | 0.27% | 69 |
|
|
2019
Q2 | $382K | Hold |
9,334
| – | – | 0.3% | 65 |
|
|
2019
Q1 | $376K | Hold |
9,334
| – | – | 0.33% | 66 |
|
|
2018
Q4 | $387K | Hold |
9,334
| – | – | 0.43% | 54 |
|
|
2018
Q3 | $390K | Buy |
9,334
+185
| +2% | +$7.12K | 0.35% | 67 |
|
|
2018
Q2 | $315K | Hold |
9,149
| – | – | 0.3% | 74 |
|
|
2018
Q1 | $308K | Hold |
9,149
| – | – | 0.32% | 74 |
|
|
2017
Q4 | $314K | Buy |
+9,149
| New | +$312K | 0.32% | 77 |
|
Other funds holding PFE
AIM
SLAM
CWP
Congress Park Capital's PFE Position: Q2 2026 in Review
Congress Park Capital increased its Pfizer (PFE) stake by 29% in Q2 2026, buying an estimated $55.6K and bringing the position to 9,551 shares worth $230K. The position accounts for 0.06% of the portfolio, ranked #119.
Congress Park Capital first reported a position in PFE in Q4 2017 and has held it in 35 quarters since. The position peaked at $1.12M in Q4 2021. 1,257 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Congress Park Capital held 9,551 shares of Pfizer worth $230K as of Q2 2026.
- Congress Park Capital bought 2,125 Pfizer shares in Q2 2026, an estimated $55.6K.
- Pfizer made up 0.06% of Congress Park Capital's portfolio in Q2 2026, its #119 holding.
- Congress Park Capital first reported a position in Pfizer in Q4 2017 and has held it in 35 quarters since.
- Congress Park Capital's Pfizer position peaked at $1.12M in Q4 2021.
- 1,257 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Congress Park Capital's 13F filing for Q2 2026, filed 14 Jul 2026.